Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
Identifieur interne : 000F60 ( PubMed/Corpus ); précédent : 000F59; suivant : 000F61Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
Auteurs : G A Mcarthur ; M. Maio ; A. Arance ; P. Nathan ; C. Blank ; M-F Avril ; C. Garbe ; A. Hauschild ; D. Schadendorf ; O. Hamid ; M. Fluck ; M. Thebeau ; J. Schachter ; R. Kefford ; M. Chamberlain ; M. Makrutzki ; S. Robson ; R. Gonzalez ; K. MargolinSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM.
DOI: 10.1093/annonc/mdw641
PubMed: 27993793
Links to Exploration step
pubmed:27993793Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.</title>
<author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name>
<affiliation><nlm:affiliation>AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Arance, A" sort="Arance, A" uniqKey="Arance A" first="A" last="Arance">A. Arance</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Hospital Clínic Barcelona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nathan, P" sort="Nathan, P" uniqKey="Nathan P" first="P" last="Nathan">P. Nathan</name>
<affiliation><nlm:affiliation>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Blank, C" sort="Blank, C" uniqKey="Blank C" first="C" last="Blank">C. Blank</name>
<affiliation><nlm:affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Avril, M F" sort="Avril, M F" uniqKey="Avril M" first="M-F" last="Avril">M-F Avril</name>
<affiliation><nlm:affiliation>University Paris Descartes, Hospital Cochin, APHP, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Garbe, C" sort="Garbe, C" uniqKey="Garbe C" first="C" last="Garbe">C. Garbe</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Tuebingen, Tuebingen.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name>
<affiliation><nlm:affiliation>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name>
<affiliation><nlm:affiliation>Angeles Clinic and Research Institute, Los Angeles, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fluck, M" sort="Fluck, M" uniqKey="Fluck M" first="M" last="Fluck">M. Fluck</name>
<affiliation><nlm:affiliation>Fachklinik Hornheide, Munster, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thebeau, M" sort="Thebeau, M" uniqKey="Thebeau M" first="M" last="Thebeau">M. Thebeau</name>
<affiliation><nlm:affiliation>Moffitt Cancer Center, Tampa, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J" last="Schachter">J. Schachter</name>
<affiliation><nlm:affiliation>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kefford, R" sort="Kefford, R" uniqKey="Kefford R" first="R" last="Kefford">R. Kefford</name>
<affiliation><nlm:affiliation>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chamberlain, M" sort="Chamberlain, M" uniqKey="Chamberlain M" first="M" last="Chamberlain">M. Chamberlain</name>
<affiliation><nlm:affiliation>Seattle Cancer Care Alliance, Seattle, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Makrutzki, M" sort="Makrutzki, M" uniqKey="Makrutzki M" first="M" last="Makrutzki">M. Makrutzki</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robson, S" sort="Robson, S" uniqKey="Robson S" first="S" last="Robson">S. Robson</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gonzalez, R" sort="Gonzalez, R" uniqKey="Gonzalez R" first="R" last="Gonzalez">R. Gonzalez</name>
<affiliation><nlm:affiliation>University of Colorado Cancer Center, Aurora.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Margolin, K" sort="Margolin, K" uniqKey="Margolin K" first="K" last="Margolin">K. Margolin</name>
<affiliation><nlm:affiliation>City of Hope, Duarte, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27993793</idno>
<idno type="pmid">27993793</idno>
<idno type="doi">10.1093/annonc/mdw641</idno>
<idno type="wicri:Area/PubMed/Corpus">000F60</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.</title>
<author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name>
<affiliation><nlm:affiliation>AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Arance, A" sort="Arance, A" uniqKey="Arance A" first="A" last="Arance">A. Arance</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Hospital Clínic Barcelona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nathan, P" sort="Nathan, P" uniqKey="Nathan P" first="P" last="Nathan">P. Nathan</name>
<affiliation><nlm:affiliation>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Blank, C" sort="Blank, C" uniqKey="Blank C" first="C" last="Blank">C. Blank</name>
<affiliation><nlm:affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Avril, M F" sort="Avril, M F" uniqKey="Avril M" first="M-F" last="Avril">M-F Avril</name>
<affiliation><nlm:affiliation>University Paris Descartes, Hospital Cochin, APHP, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Garbe, C" sort="Garbe, C" uniqKey="Garbe C" first="C" last="Garbe">C. Garbe</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Tuebingen, Tuebingen.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name>
<affiliation><nlm:affiliation>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name>
<affiliation><nlm:affiliation>Angeles Clinic and Research Institute, Los Angeles, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fluck, M" sort="Fluck, M" uniqKey="Fluck M" first="M" last="Fluck">M. Fluck</name>
<affiliation><nlm:affiliation>Fachklinik Hornheide, Munster, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thebeau, M" sort="Thebeau, M" uniqKey="Thebeau M" first="M" last="Thebeau">M. Thebeau</name>
<affiliation><nlm:affiliation>Moffitt Cancer Center, Tampa, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J" last="Schachter">J. Schachter</name>
<affiliation><nlm:affiliation>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kefford, R" sort="Kefford, R" uniqKey="Kefford R" first="R" last="Kefford">R. Kefford</name>
<affiliation><nlm:affiliation>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chamberlain, M" sort="Chamberlain, M" uniqKey="Chamberlain M" first="M" last="Chamberlain">M. Chamberlain</name>
<affiliation><nlm:affiliation>Seattle Cancer Care Alliance, Seattle, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Makrutzki, M" sort="Makrutzki, M" uniqKey="Makrutzki M" first="M" last="Makrutzki">M. Makrutzki</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robson, S" sort="Robson, S" uniqKey="Robson S" first="S" last="Robson">S. Robson</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gonzalez, R" sort="Gonzalez, R" uniqKey="Gonzalez R" first="R" last="Gonzalez">R. Gonzalez</name>
<affiliation><nlm:affiliation>University of Colorado Cancer Center, Aurora.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Margolin, K" sort="Margolin, K" uniqKey="Margolin K" first="K" last="Margolin">K. Margolin</name>
<affiliation><nlm:affiliation>City of Hope, Duarte, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title>
<idno type="eISSN">1569-8041</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27993793</PMID>
<DateCreated><Year>2016</Year>
<Month>12</Month>
<Day>20</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>04</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>28</Volume>
<Issue>3</Issue>
<PubDate><Year>2017</Year>
<Month>Mar</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
<ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.</ArticleTitle>
<Pagination><MedlinePgn>634-641</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdw641</ELocationID>
<Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM.</AbstractText>
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">Patients with BRAFV600 mutated melanoma with BM were enrolled into cohort 1 (previously untreated BM) and cohort 2 (previously treated BM) and received vemurafenib (960 mg BID) until disease progression (PD) or intolerance. Primary endpoint was best overall response rate (BORR) in the brain in cohort 1 that was evaluated using modified RECIST 1.1 criteria using lesions ≥0.5 cm to assess response.</AbstractText>
<AbstractText Label="Results" NlmCategory="UNASSIGNED">146 patients were treated (cohort 1 n = 90; cohort 2 n = 56), 62% of whom were male. Median (range) time since diagnosis of BM: 1.0 (0-9) month in cohort 1 and 4.2 (1-68) months in cohort 2. Median duration of treatment was 4.1 months (range 0.3-34.5) in cohort 1 and 4.1 months (range 0.2-27.6) in cohort 2. Intracranial BORR in cohort 1 by an independent review committee (IRC) was 18% (2 CRs, 14 PRs). Extracranial BORR by IRC was 33% in cohort 1 and 23% in cohort 2. Median PFS (brain only, investigator-assessed) was 3.7 months (range 0.03-33.4; IQR 1.9-5.6) in cohort 1 and 4.0 months (range 0.3-27.4; IQR 2.2-7.4) in cohort 2. Median OS was 8.9 months (range 0.6-34.5; IQR 4.9-17.0) in cohort 1 and 9.6 months (range 0.7-34.3; IQR 4.5-18.4) in cohort 2. Adverse events (AEs) were similar in type, grade and frequency to other studies of single-agent vemurafenib. Grade 3/4 AEs occurred in 59 (66%) patients in cohort 1 and 36 (64%) in cohort 2. Overall, 84% of patients died during the study (86% in cohort 1 and 80% in cohort 2), mainly due to disease progression.</AbstractText>
<AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McArthur</LastName>
<ForeName>G A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maio</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>AOU Senese Policlinico Santa Maria Alle Scotte, Siena, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Arance</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Clínic Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nathan</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Blank</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Avril</LastName>
<ForeName>M-F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo><Affiliation>University Paris Descartes, Hospital Cochin, APHP, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Garbe</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Tuebingen, Tuebingen.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hauschild</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schadendorf</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hamid</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Angeles Clinic and Research Institute, Los Angeles, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fluck</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Fachklinik Hornheide, Munster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thebeau</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schachter</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Chaim Sheba Medical Centre, Oncology Institute, Ramat-Gan, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kefford</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Crown Princess Cancer Centre Westmead Hospital and Department of Clinical Medicine, Macquarie University, Sydney NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chamberlain</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Seattle Cancer Care Alliance, Seattle, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Makrutzki</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robson</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gonzalez</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>University of Colorado Cancer Center, Aurora.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Margolin</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>City of Hope, Duarte, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Ann Oncol</MedlineTA>
<NlmUniqueID>9007735</NlmUniqueID>
<ISSNLinking>0923-7534</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BRAFV600 mutated melanoma</Keyword>
<Keyword MajorTopicYN="N">brain metastases</Keyword>
<Keyword MajorTopicYN="N">phase 2 study</Keyword>
<Keyword MajorTopicYN="N">vemurafenib</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27993793</ArticleId>
<ArticleId IdType="pii">mdw641</ArticleId>
<ArticleId IdType="doi">10.1093/annonc/mdw641</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:27993793 |texte= Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27993793" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |